Wynder Given The American Cancer Society Award at AACR

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 6
Volume 7
Issue 6

NEW ORLEANS--Ernst L. Wynder, MD, DSc, Dr.med.h.c., has received the seventh AACR American Cancer Society Award. Dr. Wynder is president and medical director of the American Health Foundation in New York.

NEW ORLEANS--Ernst L. Wynder, MD, DSc, Dr.med.h.c., has received the seventh AACR American Cancer Society Award. Dr. Wynder is president and medical director of the American Health Foundation in New York.

The award, given yearly to honor research accomplishments in cancer epidemiology, biomarkers, and prevention, was presented at the 89th annual meeting of the American Association for Cancer Research (AACR).

Dr. Wynder was chosen for this year’s award because he was the first scientist in the United States to demonstrate the link between smoking and lung cancer.

At the award presentation, Anna D. Barker, PhD, president and CEO of OXIS International, Portland, Oregon, described how Dr. Wynder began his research while still a medical student. He went to 50 hospitals to interview 684 people with lung cancer and 1,332 controls about their smoking history. This survey established that only eight of the lung cancer patients did not smoke.

Results Published in 1950

Dr. Wynder published his results jointly with surgeon Ewarts Graham, MD, in 1950 in the Journal of the American Medical Association, but it took years for these results to be accepted.

Since that seminal article in 1950, Dr. Wynder has published more than 750 papers. He helped show that smoking also causes cancer of the mouth, larynx, pharynx, and esophagus, and leads to an increased risk for cancer of the pancreas, kidney, and bladder. He also established the American Health Foundation, an institute devoted to research on cancer causation and prevention.

Michael Thun, MD, vice president for epidemiology and surveillance research of the American Cancer Society, presented the award to Dr. Wynder. "He’s a pioneer in the tobacco wars," Dr. Thun said. "He has been way ahead of his time in recognizing the importance of different disciplines working together."

Recent Videos
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.
4 experts are featured in this series.
Based on a patient’s SCLC subtype, and Schlafen 11 status, patients will be randomly assigned to receive durvalumab alone or with a targeted therapy in the S2409 PRISM trial.
4 experts are featured in this series.
Daniel Peters, MD, aims to reduce the toxicity associated with AML treatments while also improving therapeutic outcomes.
Numerous clinical trials vindicating the addition of immunotherapy to first-line chemotherapy in SCLC have emerged over the last several years.
Patients with AML will experience different toxicities based on the treatment they receive, whether it is intensive chemotherapy or targeted therapy.
A younger patient with AML who is more fit may be eligible for different treatments than an older patient with chronic medical conditions.
Breast cancer care providers make it a goal to manage the adverse effects that patients with breast cancer experience to minimize the burden of treatment.
Social workers and case managers may have access to institutional- or hospital-level grants that can reduce financial toxicity for patients undergoing cancer therapy.
Related Content